Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
Arthritis Associates of Mississippi
mi
from
Jackson, MS
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
Arthritis Associates of Mississippi
mi
from
Jackson, MS
Click here to add this to my saved trials
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
East Penn Rheumatology Associates, P.C.
mi
from
Bethlehem, PA
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
East Penn Rheumatology Associates, P.C.
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
Seattle Rheumatology Associates
mi
from
Seattle, WA
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
Seattle Rheumatology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
Physician Research Collaboration
mi
from
Lincoln, NE
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
Box Arthritis and Rheumatology of the Carolina's
mi
from
Charlotte, NC
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
Box Arthritis and Rheumatology of the Carolina's
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated:  7/24/2015
Local Institution
mi
from
Capital Federal,
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Status: Enrolling
Updated: 7/24/2015
Local Institution
mi
from
Capital Federal,
Click here to add this to my saved trials
Treatment of Hypovitaminosis D in Rheumatoid Arthritis
Treatment of Hypovitaminosis D in Rheumatoid Arthritis
Status: Enrolling
Updated:  7/27/2015
University of Wisconsin
mi
from
Madison, WI
Treatment of Hypovitaminosis D in Rheumatoid Arthritis
Treatment of Hypovitaminosis D in Rheumatoid Arthritis
Status: Enrolling
Updated: 7/27/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement
Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement
Status: Enrolling
Updated:  7/28/2015
Biomet Orthopedics, LLC
mi
from
Warsaw, IN
Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement
Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement
Status: Enrolling
Updated: 7/28/2015
Biomet Orthopedics, LLC
mi
from
Warsaw, IN
Click here to add this to my saved trials
Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis
Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis: Clinical Trial and Investigations on Dendritic Cells
Status: Enrolling
Updated:  7/31/2015
Indiana University
mi
from
Indianapolis, IN
Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis
Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis: Clinical Trial and Investigations on Dendritic Cells
Status: Enrolling
Updated: 7/31/2015
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Phoenix, AZ
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Miami, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Tuscon, AZ
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Tuscon, AZ
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Anahiem, CA
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Anahiem, CA
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigator Site
mi
from
Clearwater, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigator Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Coral Gables, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Coral Gables, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Fleming Island, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Fleming Island, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Pinellas Park, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Venice, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Venice, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Marietta, GA
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Marietta, GA
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
South Bend, IN
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
South Bend, IN
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Springfield, MO
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Springfield, MO
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigator Site
mi
from
Albuquerque, NM
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Statesville, NC
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Statesville, NC
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis
mi
from
San Antonio, TX
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Bruxelles,
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Tucson, AZ
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
La Jolla, CA
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Victorville, CA
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Victorville, CA
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Sarasota, FL
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Rock Island, IL
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Rock Island, IL
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Springfield, IL
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Lexington, KY
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Lansing, MI
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Freehold, NJ
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Portland, OR
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Duncansville, PA
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Tacoma, WA
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
mi
from
Sofia,
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
mi
from
Sofia,
Click here to add this to my saved trials
Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study
Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study and Preliminary Validation Effort
Status: Enrolling
Updated:  8/18/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study
Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study and Preliminary Validation Effort
Status: Enrolling
Updated: 8/18/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Huntsville, AL
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Paradise Valley, AZ
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Palm Desert, CA
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Jupiter, FL
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Jupiter, FL
Click here to add this to my saved trials
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  8/27/2015
Clinical Research Facility
mi
from
Sarasota, FL
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 8/27/2015
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials